Mylan Pharmaceuticals Private Limited
Prestige Tech Park,Platina-3,
7th to 12th floor, Prestige Tech Park,
- Mylan’s history, mission and values tell the story of who we are as a company. We began more than 50 years ago as a pharmaceutical distributor, providing products to customers in rural communities.
- Today, we’re one of the world’s leading pharmaceutical companies, with a significant and growing presence in India. We sell our products in approximately 165 countries and territories. What hasn’t changed is our dedication to providing access to high quality medicine.
- First known as Milan, the company starts doing business in White Sulphur Springs, West Virginia. U.S. Army chums, Milan “Mike” Puskar and Don Panoz flip a coin to see who will name the business and who will be the company’s first president. They start distributing products to doctors and chemists from an old Pontiac Bonneville.
Mylan in India:
- Mylan is one of the world’s leading global pharmaceutical companies, with a significant and growing presence in India. We have a workforce of more than 30,000 people, approximately half of whom are based in India. Our broad portfolio includes generic and brand name products in a variety of dosage forms, which are sold in about 165 countries and territories.
- Mylan’s history in India began in 2007 with the acquisition of Matrix Laboratories Limited. The deal transformed Mylan overnight into one the world’s largest manufacturers of active pharmaceutical ingredients (API) and allowed us to vertically integrate the production of our finished dosage form (FDF) medicines.
- Today, Mylan’s manufacturing platform includes more than 40 facilities, 25 of which are located in India. Those 25 facilities include all nine of our API facilities and 15 of our FDF facilities, which manufacture our high quality medicines for markets all over the world, including emerging markets. Our manufacturing capabilities in India include a range of dosage forms, such as tablets, capsules and injectables, in a wide variety of therapeutic categories. Our commercial businesses based in India market hiqh quality API to third parties around the world and antiretroviral products for people living with HIV/AIDS. Today, nearly 50% of those receiving treatment for the disease in the developing world rely on a Mylan product, all of which are made by us in India. In fact, Mylan is India’s third largest pharmaceutical exporter.
- In addition, Mylan has a growing commercial presence domestically. Our current franchises include Critical Care, Hepato Care, HIV Care, Onco Care and Women’s Care.
- Further, our presence in India goes beyond manufacturing, sales and marketing. Hyderabad is home to one of Mylan’s three global R&D centers of excellence. The center has extensive experience working with health authorities from multiple countries. It also is fully integrated with the company’s global R&D function, creating a unique and efficient, ‘round-the-clock research, development, clinical and regulatory capability.
- The business and affairs of Mylan Inc. are managed under the oversight of the company’s Board of Directors. The company’s bylaws and corporate governance principles detail certain of the Directors’ duties, rights and responsibilities.
- Currently, the Board has seven committees, each operating pursuant to a written charter.
- The Chief Executive Officer (CEO) and other senior leaders oversee management of company business. Duties and standards of conduct for employees, officers and directors are set forth in the company’s Code of Business Conduct and Ethics, as well as in the Code of Ethics for the CEO, Chief Financial Officer (CFO) and Corporate Controller (CC).
- At Mylan, our mission is to provide the world’s 7 billion people access to high quality medicine. We have more than 15,000 dedicated individuals working in India who are critical to helping the company deliver on this promise.
- Mylan’s businesses in India are helping fulfill the unmet medical needs of not only Indian patients through our domestic business, but also patients around the world through our third-party active pharmaceutical ingredient (API), antiretrovirals (ARV) and emerging markets businesses.
ARVs and Emerging Markets:
Through our operations in India, Mylan has earned a reputation for being one of the world’s leading suppliers of high quality, affordable ARV medicines to treat HIV/AIDS. We supply our API and finished dosage form ARVs to more than 100 countries around the world. Today, nearly 50% of those receiving treatment for the disease in the developing world rely on a Mylan product. We export our ARV products as well as many other medicines that we manufacture in India, including tablets, capsules and injectables, to emerging markets around the world, such as Africa, Latin America, the Middle East, North Africa and South East Asia.
India Domestic Business
In 2012, Mylan launched its domestic business in India with a comprehensive ARV portfolio. Since then, the company has expanded its sales force in India to include more than 400 representatives and launched Critical Care, Hepato Care, HIV Care, Oncology Care and Women’s Care segments. In addition to providing a broad range of products, Mylan has launched several educational initiatives in India to support medical professionals in their efforts to more effectively treat their patients and help patients better manage their disease.
Critical Care Products:
- The bacterial disease burden in India is among the highest in the world, and hospital-acquired infections are of particular concern. These infections pose a great risk to the timely recovery of patients and are associated with high mortality rates. As a result, critical care medicines play a vital role in reducing morbidity and mortality. In addition, critical care patients have life-threatening conditions requiring healthcare professionals to often use a multi-pronged treatment approach that can affect the cost of daily therapy.
- To satisfy the unmet medical needs of seriously ill patients in intensive care units, Mylan India launched its Critical Care division in 2014, with several high quality, affordable antifungal, antibacterial and anticoagulant therapies.
Hepato Care Products:
- Viral hepatitis, caused by hepatitis viruses A through E, is a significant public health problem in India. An estimated 40 million people in India have chronic hepatitis B infection, constituting approximately 11% of the estimated global burden. Hepatitis C affects about 12 million patients in India. Both of these blood-borne infections have high risk of chronicity with progression to advanced liver disease and are associated with development of hepatocellular carcinoma, a type of liver cancer, underscoring the need for increased access to high quality, affordable and effective therapy in India.
- Mylan India launched its Hepato Care division in January 2015 to respond to this public health concern and help meet the unmet medical needs of the patients in India who do not currently have access to critical medicines.
HIV Care Products:
India is home to the world’s third largest population of people with HIV/AIDS, with approximately 2.5 million people living with the disease, of which fewer than 36% have access to treatment. Recognizing the critical need to further increase access to HIV/AIDS care in India, Mylan launched its domestic business in 2012 with a comprehensive portfolio of ARVs, all of which are manufactured at Mylan’s state-of-the-art facilities in India.
Onco Care Products:
- In India, slightly more than one million new cases of cancer are diagnosed every year in a population of 1.2 billion, and the number of new cancer cases is projected to nearly double within the next 20 years. In 2012 alone, an estimated 600,000 to 700,000 deaths in India were caused by cancer.
- Delivering affordable and effective cancer care is one of India’s greatest public health challenges. Mylan is helping to address this growing public health concern through its Onco Care division, launched in January 2014. Mylan’s oncology portfolio in India includes high quality, affordable cancer-related cytotoxic and targeted therapies for common types of cancer, such as breast, lung and colorectal.
- In February 2014, Mylan launched the world’s first Trastuzumab biosimilar under the brand name HertrazTM for the treatment of HER2-positive metastatic breast cancer. To further its commitment to providing holistic breast cancer care, Mylan launched Ashray, a unique initiative that addresses the gaps in HER2-positive metastatic breast cancer management by offering patients financial, emotional and psychological support.
Women’s Care Products:
- Women in India face a number of health challenges, including risks of miscarriages, infertility and other post-menopause related complications. Approximately one in five pregnancies in Indian women end in miscarriage. In addition, women who are in post-menopause may experience various short-, medium- and long- term complications, such as urogenital atrophy or osteoporosis.
- Mylan aims to tackle these health issues through its Women’s Care segment, which focuses on treatments such as hormone replacement therapy, pre- and post-natal supplementation, post-menopause care and in-vitro fertilization treatments, such as follicle-stimulating hormones, human menopausal gonadotropins and human chorionic gonadotropins.
- In addition to launching our innovative, high quality product portfolio, Mylan helps strengthen the capabilities of healthcare providers in this area through training programs and workshops, working together with the medical community and non-government organizations to address areas of concern in women’s health and improve timely access to appropriate high quality treatment.
Krebs Biochemicals & Industries Limited
click above to visit
this company / organization